HCV Archives – Page 20 of 29 – Treatment Action Group

Training Manual for Treatment Advocates: Hepatitis C Virus and Coinfection with HIV

November 12, 2013
Chad Cipiti

November 2013 By Karyn Kaplan and Tracy Swan The purpose of this manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment…

TAGline Fall 2013

October 4, 2013
Chad Cipiti

The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.

Letter Urging UNITAID to Prioritize HIV/HCV Coinfection

September 25, 2013
Chad Cipiti

TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.

HIV i-Base/Treatment Action Group 2013 Pipeline Report calls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible

June 30, 2013
Chad Cipiti

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

2013 Pipeline Report

June 29, 2013
Chad Cipiti

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development: Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan

Help Paying for HIV and Hepatitis Treatment

April 8, 2013
Chad Cipiti

Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment. The Fair Pricing Coalition (FPC) has negotiated co-pay…

The “G” Word

April 8, 2013
Chad Cipiti

Gilead’s greed gives rise to a slew of advocacy priorities By Tracy Swan Activists are decrying Gilead’s refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising…

Advancing Research, Securing Access

April 5, 2013
Chad Cipiti

By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…

TAGline Spring 2013

April 5, 2013
Chad Cipiti

Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.

Hepatitis C and the IL28B Gene

April 2, 2013
Chad Cipiti

April 2013 What predicts response to hepatitis C virus (HCV) treatment? Many things help predict the likelihood of being cured (called sustained virological response or SVR) by pegylated interferon (PEG-IFN) and ribavirin (RBV). Making sure to take all medications as…